Zimmer Biomet Holdings, Inc. has entered into a new financing agreement as of June 27, 2025. The company has secured a five-year revolving credit facility valued at $1.5 billion through an agreement with JPMorgan Chase Bank, N.A., acting as the administrative agent, along with other lenders. This Five-Year Revolving Credit Agreement, which is unsecured, includes options for two one-year extensions, subject to lender consent. Additionally, Zimmer Biomet has the ability to request an increase of the facility by up to $500 million. The funds will be utilized for general corporate purposes, with interest rates set at floating rates based on either an adjusted Term SOFR or an alternate base rate, plus an applicable margin. This new agreement replaces a previous five-year credit arrangement, which was terminated upon entering the new agreement.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。